Modulation of Target Antigen Density Improves CAR T Cell Functionality and Persistence

PURPOSE: Chimeric antigen receptor T cell (CART) therapy targeting CD22 induces remission in 70% of patients with relapsed/refractory acute lymphoblastic leukemia (ALL). However, the majority of post-CD22 CART remissions are short and associated with reduction in CD22 expression. We evaluate the imp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Ramakrishna, Sneha, Highfill, Steven L, Walsh, Zachary, Nguyen, Sang M, Lei, Haiyan, Shern, Jack F., Qin, Haiying, Kraft, Ira, Stetler-Stevenson, Maryalice, Yuan, Constance M., Hwang, Jennifer, Feng, Yang, Zhu, Zhongyu, Dimitrov, Dimiter, Shah, Nirali N., Fry, Terry J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8290499/
https://ncbi.nlm.nih.gov/pubmed/31110075
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3784
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados